Sarepta Therapeutics (SRPT) Tops Q2 EPS by 92c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), $0.92 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $261.2 million versus the consensus estimate of $259.79 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
• Canaan Inc. (CAN) PT Lowered to $2 at BTIG